Evidence map›Paper›PMID 35448256›Full record

ArticleBiosensors2022

Revisiting the Resazurin-Based Sensing of Cellular Viability: Widening the Application Horizon.

Darja Lavogina, Helen Lust, Maris-Johanna Tahk, Tõnis Laasfeld, Hans Vellama, Naila Nasirova, Markus Vardja, Kattri-Liis Eskla, Andres Salumets, Ago Rinken and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
28.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Antimicrobial agents and chemotherapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Darja LavoginaInstitute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.
Helen LustInstitute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.
Maris-Johanna TahkInstitute of Chemistry, University of Tartu, 50411 Tartu, Estonia.ORCID 0000-0002-4566-9192
Tõnis LaasfeldInstitute of Chemistry, University of Tartu, 50411 Tartu, Estonia.
Hans VellamaDepartment of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia.
Naila NasirovaInstitute of Chemistry, University of Tartu, 50411 Tartu, Estonia.
Markus VardjaDepartment of Radiotherapy and Oncological Therapy, Tartu University Hospital, 50406 Tartu, Estonia.
Kattri-Liis EsklaDepartment of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia.
Andres SalumetsInstitute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.
Ago RinkenInstitute of Chemistry, University of Tartu, 50411 Tartu, Estonia.ORCID 0000-0002-7238-749X
Jana JaalInstitute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.
University of Tartu · EETartu University Hospital · EECompetence Centre on Health Technologies (Estonia) · EEKarolinska Institutet · SE

Funding

Enterprise Estonia (Estonia) EU48695Estonian Research Council PRG1076Estonian Research Council PRG454Estonian Research Council PSG431Estonian Research Council PUT1077European Commission Horizon 2020 Innovation, ERIN, EU952516European Regional Development Fund 2014-2020.4.01.15-0012University of Tartu Internal financing from the Institute of Clinical Medicine
6 · The paper itself

Abstract

Since 1991, the NAD(P)H-aided conversion of resazurin to fluorescent resorufin has been widely used to measure viability based on the metabolic activity in mammalian cell culture and primary cells. However, different research groups have used divergent assay protocols, scarcely reporting the systematic optimization of the assay. Here, we perform extensive studies to fine-tune the experimental protocols utilizing resazurin-based viability sensing. Specifically, we focus on (A) optimization of the assay dynamic range in individual cell lines for the correct measurement of cytostatic and cytotoxic properties of the compounds; (B) dependence of the dynamic range on the physical quantity detected (fluorescence intensity versus change of absorbance spectrum); (C) calibration of the assay for the correct interpretation of data measured in hypoxic conditions; and (D) possibilities for combining the resazurin assay with other methods including measurement of necrosis and apoptosis. We also demonstrate the enhanced precision and flexibility of the resazurin-based assay regarding the readout format and kinetic measurement mode as compared to the widely used analogous assay which utilizes tetrazolium dye MTT. The discussed assay optimization guidelines provide useful instructions for the beginners in the field and for the experienced scientists exploring new ways for measurement of cellular viability using resazurin.

Indexed as

Antineoplastic AgentsXanthenesAnimalsBiological AssayCell SurvivalMammalsOxazinesAntineoplastic AgentsOxazinesresazurinXanthenesabsorbanceAlamar Bluecell viabilityfluorescencehypoxiaresazurinresorufin

Identifiers

PMID35448256
PMCPMC9032648
OpenAlexW4220930192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.